Clariane share testing support at €3.23, lagging SBF 120
The retirement homes and home care services group extends its decline in mid-afternoon trading, in a lower-oriented Paris market. It finds itself at the bottom of the broadened index table, testing a technical threshold already under surveillance.
A share stuck at its support level, far from its three moving averages
The Clariane share falls 1.88% to €3.24, just over 0.3% above its support at €3.23. The decline is part of a lengthy downturn: the share loses 15.09% over one month and 19.28% over three months. The price remains below its three moving averages, 7.95% below the 20-day MA (€3.52) and 14.74% below the 50-day MA (€3.80), depicting a bearish slope without sustained rebound since the start of the school year.
The RSI at 34.99 is close to the oversold zone. During today's session, Clariane ranks among the sharpest declines on the SBF 120, which itself falls 0.62%, and already fell below €3.30 on Monday. Emeis, another retirement home operator, declines 1.40% on Tuesday and drops 17.25% over one month, a trajectory similar to Clariane's.
First-half results and financing initiatives serve as benchmarks
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
When publishing first-half 2026 results on July 29, the group targeted an improvement in its EBITDA margin of 100 to 150 basis points by end-2026, supported by progressive increases in occupancy rates. It also cited inflationary pressure on costs among its risks, despite tariff gains. On the financing side, Clariane signed on September 22 a €700 million renewable credit line maturing in 2031, shortly after completing a €500 million senior bond placement on September 8.
The session is also unfolding against a backdrop of elevated French rates: the 10-year OAT stands at 4.93%, its highest level since July 2002. The €3.23 support level is the threshold the share is testing this afternoon.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 699 millions d'euros
Quarterly revenue: 2 699 millions d'euros
Revenue growth: 1,6 %
EBITDA: 524 millions d'euros
EBITDA margin: 10,4 %
Net income: -47,5 millions d'euros
Free cash flow: 20 millions d'euros
3 020 millions d'euros
Guidance from the release
Le Groupe s'appuiera principalement sur la poursuite de l'amélioration de la performance opérationnelle et le maintien d'une stricte discipline d'investissements
Risks mentioned
Environnement géopolitique complexe affectant les opérations de refinancement
Exposition aux épisodes climatiques frappant durement certains territoires en Europe
Pression inflationniste continue sur les coûts opérationnels malgré les gains tarifaires
Opportunities identified
Amélioration de la marge EBITDA de 100-150 points de base d'ici fin 2026
Croissance des volumes d'activité portée par l'augmentation progressive des taux d'occupation
Refinancement réussi de €1 063m renforçant la flexibilité financière et réduisant le coût de la dette
Outlook / guidance
Expected revenue: 5 522 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.